Antibody Engineering & Therapeutics Europe
Join us in Amsterdam or digitally for Antibody Engineering & Therapeutics Europe, the region’s leading antibody conference for accelerating next-generation antibodies to commercial success.
- Thierry Wurch, Ph.D., Senior VP, Integrated Biologics Discovery at Evotec
- Barbara Bachler-Konetzki, Group Leader Antibody Drug Discovery at Evotec
- Dan Ozanne, VP Business Development (Europe) at Just-Evotec Biologics
EVOiR&D: An integrated discovery and development platform to deliver best-in-class biologics at Evotec
At Evotec, we discover, develop and manufacture novel medicines for hard-to-treat diseases through efficient partnerships with academia, biotechs and pharma. Our discovery efforts focus on data-driven precision medicine and early disease relevance to improve success rates in identifying best-in-class therapeutics.
Regarding antibody-based modalities, we have developed an integrated discovery platform ranging from target validation, antibody discovery and optimization, in vitro/in vivo pharmacology, PK, and toxicology to select the best clinical candidates. By applying both humanized, mouse-derived hybridoma and phage display (from immune and synthetic antibody libraries) coupled to automated HTS antibody screening and AI/ML-based optimization, antibody hits are selected to best fit their intended modality, (e.g. mAbs, ADCs, bispecifics). A particular emphasis is placed on integrating good manufacturing properties for the selected antibody sequence. Examples of integrated discovery flowcharts will be discussed.
Presented by Thierry Wurch, Ph.D., Senior VP, Integrated Biologics Discovery at Evotec
AI-Derived Antibodies are novel, diverse and pharmacologically active against multiple SARS-CoV-2 strains
Presented by Barbara Bachler-Konetzki, Group Leader Antibody Drug Discovery at Evotec
Learn more about Antibody Engineering & Therapeutics Europe
Barbara Bachler-KonetzkiGroup Leader, In Vitro Pharmacology
Barbara received her PhD in Biomedicine and Biotechnology from the University of Veterinary Medicine in Vienna, Austria in collaboration with the Harvard Medical School / Dana-Farber Cancer Institute in Boston, USA where she focused on the profiling of protective anti-HIV antibody responses upon vaccination. After moving back to Europe, she continued to work on antibodies at MorphoSys, a biotech company based in Munich, Germany, well-known for the discovery and development of therapeutic antibodies using human antibody libraries by applying the in silico phage display technology. During this time, Barbara successfully discovered a novel acting therapeutic antibody, and progressed it all the way from concept to pre-clinical candidate nomination. In 2021, this molecule entered clinical phase 1 testing in immune oncology. Joining Evotec in 2018, she played a key role in the establishment of the streamlined hybridoma platform and the implementation of the ATX-Gx™ mice from Alloy as source of fully human antibodies. She is now leading a group of scientists and technicians supporting internal and external antibody programmes from target identification to lead candidate nomination.
Thierry WurchSVP Integrated Biologics Discovery
Thierry joined Evotec in May 2022 as SVP Integrated Biologics Discovery. He has more than 22 years of expertise in the antibody R&D space primarily in Oncology and immune-oncology. Thierry held positions of growing strategic importance from head of an antibody discovery and engineering department (Pierre Fabre, 2003-2011), head of immunotherapy discovery research activities (Servier, 2011-2017) then moving to BD-oriented activities and heading external innovation for Oncology (Servier, 2017-2020 and Ipsen 2020-2022). Thierry is also Chairman of the antibody sub-committee at NC-IUPHAR, member of the Editorial board of mAbs Journal and Distinguished Advisor of The Antibody Society.